Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase III ASPIRE study and prospective anti-CD38 therapy for myeloma

Phase III ASPIRE study of carfilzomib and prospective anti-CD38 monoclonal antibody therapy

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses recent advances in the treatment of multiple myeloma.

The phase III ASPIRE study showed that adding the proteasome inhibitor, carfilzomib, to the standard doublet therapy of lenalidomide and dexamethasone resulted in a higher progression-free survival for relapsed multiple myeloma patients.

CD38 represents a promising target for monoclonal antibody-based immunotherapy. Novel anti-CD38 monoclonal antibodies, daratumumab and SAR650984, are undergoing clinical investigation.